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BACKGROUND
Antibody Mediated Rejection (AMR)

Heart and Kidney Transplant

TREATMENT
1,2

• Rejection that occurs due to antibodies against donor-specific antigen (DSA)

Treatment of AMR

CELL-BASED
ASSAYS

CDC cross-match
Donor lymphocytes

• Risk Factors

Fluorescent-conjugated
anti-human globulin

– Prior transplantation

• Occurs within minutes of graft transplantation causing death of the graft

SOLID PHASE
ASSAYS

Purified HLA antigens
embedded in polystyrene
microspheres

• Due to pre-formed antibodies or antibodies that develop de novo after transplantation

Luminex

• Antithymocyte globulin

• Patient received 5 sessions of plasmapheresis alternating with thymoglobulin
for 2 doses based upon the absolute lymphocyte count on POD 6-16

• Plasmapheresis

• On POD 17, the patient received rituximab 490 mg (375mg/m2)
• IVIG 500 mg/kg for 4 doses was administered on POD 17-20

Rituximab in the Treatment of AMR6-11

Post Operative Clinical Course

– Monoclonal antibody that binds to CD20 antigen, found predominantly on pre-B
and mature B lymphocytes
1,3,4

Diagnosis of Antibody Mediated Rejection

• Endomyocardial biopsy is now considered the standard approach to
diagnose AMR

– CD20 regulates early steps in the activation process for cell cycle initiation and
differentiation

– Biopsy evaluates:

– Attenuates the production of antibodies against DSA, leading to decreased rejection

• Evidence for Use
– Number of case reports and case series have been published regarding the use
of rituximab post-heart transplant for the treatment of AMR, most of which
showing positive outcomes

– Intravascular macrophages

• Immunologic Findings

• No prospective studies published at this time

– Complement and HLA deposition
• C4d and CD68 staining

• Presence of donor-specific antibodies is not required for a diagnosis of AMR
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Pathologic AMR (pAMR) Classification
• pAMR0 – Negative for pathologic AMR

• pAMR1 (+I) – Immunopathologic findings positive and histological findings
negative
• pAMR1 (+H) – Histological findings positive and immunopathologic findings
negative

– Few studies have investigated the use of rituximab in the setting of AMR post
kidney transplant

Population

Doses of
Rituximab

Other Treatments
Received

Results

27 patients

1

Thymoglobulin and
plasmapheresis

At mean follow-up of 605 days,
only 3 kidney grafts were lost

Plasmapheresis,
mycophenolate, tacrolimus,
and steroids

81% graft survival at 20 months

Plasmapheresis and IVIG

90% two-year graft survival for the
rituximab group compared to 60%
in control group

High-dose IVIG

91.7% graft survival with rituximab
and high dose IVIG compared to
50% for high dose IVIG alone

8 patients

26 patients
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2

• pAMR2 – Histological findings and immunopathologic findings are positive
• pAMR3 – Severe AMR with histological findings including interstitial hemorrhage,
capillary fragmentation, mixed inflammatory infiltrates, and marked edema;
associated with profound hemodynamic dysfunction and poor clinical outcomes

– Donor-specific anti-HLA antibodies will bind to donor cells and initiate the complement cascade resulting in lysis of donor lymphocytes

12 patients

2

• Many institutions do include rituximab as an option for the treatment of AMR
post heart transplant

– Percentage of lysis is quantified through flow cytometry

Immunopathology

– Latex beads bound with a single HLA are mixed with patient serum
– Antibodies bind to respective antigen-coated bead
– Antibodies are tagged with an IgG fluorescent carrier

– Identity and quantity of anti-HLA antibodies is established through intensity of
the fluorescence
– Greater intensity of antibodies in vitro are potentially more cytotoxic in vivo

• Virtual crossmatch through United Network of Organ Sharing database

Histology

– The fluorescence can be detected through flow cytometry

-

PATIENT CASE

-

+

pAMR0

pAMR1 (I+)

Patient History
• 27 year old female
• Past medical history
– Chronic kidney disease

pAMR2
+

pAMR1 (H+)

POD 27

POD 42

• Patient
discharged home
without inotropic
support

• Received
2nd dose of
rituximab

6

14

17

27

28

42

POD 6

POD 17

POD 28

• RHC and biopsy; RHC findings
consistent with heart failure
• Biopsy revealed grade 2R (3A)
cellular rejection and grade 2 AMR
(C4d and CD68 strongly positive)
• Initiated plasmapheresis and
thymoglobulin (POD 6-16) with
improvement in EF and cardiac index

• Received first dose
of rituximab
• Received IVIG
(POD 17-20)

• 3rd RHC and biopsy;
RHC findings similar to that
of POD 14
• Biopsy showed grade
1R (1A) cellular rejection,
however staining for C4d and
CD68 were weakly positive

Rituximab for the Treatment of AMR post kidney transplant

– May impact aggressiveness of treatment

• Solid phase assays – Gold standard

POD 1
• Witnessed cardiac arrest;
promptly resuscitated
• ECHO – moderate to severe
BiV dysfunction (EF 30-35%)

1

– Causes a profound depletion of B cells

– Activated endothelium

POD 14
• 2nd RHC and biopsy; RHC
findings greatly improved
• Biopsy revealed grade 1R
(1A) cellular rejection and
staining for C4d and CD68
remained positive

• Hypothetical Use for AMR

– Routine biopsy surveillance is standard practice as symptoms are often vague
• Histologic Findings

– Donor T and B cells are incubated with recipients’ sera and complements

Course of Therapy

• Pharmacology

• Due to antibodies that mediate chronic graft injury

• Cell-based assays

– Grade 2 AMR (C4d and CD68 strongly positive)

• Bortezomib

• Occurs during the years following transplantation

• Detection of anti-human leukocyte antigen (HLA) antibodies

• Intravenous immunoglobulin (IVIG)

• Rituximab

Fluorescentconjugate antihuman globulin

– Chronic

Donor Matching1,2,3

– Grade 2R (3A) cellular rejection

• IV steroids

ELISA

• Right heart catheterization (RHC) on POD 6 consistent with acute heart failure

• Pulse steroids (oral)

– Acute Symptomatic AMR treatment options
Purified HLA antigens
directly immobilized on
the surface of microtitre
plates

• On post-operative day (POD) 1 the patient experienced a witnessed cardiac
arrest and was quickly resuscitated
• Endomyocardial biopsy on POD 6 revealed:

• Targeting higher tacrolimus or cyclosporine levels

• Rarely occurs now due to universal cross-matching

• Occurs within a few days of transplantation causing graft dysfunction

Flow cross-match

Recipient’s sera
containing anti-HLA
donor-specific
antibodies

• Due to pre-formed antibodies present in high titers

– Acute

• At this time, there are no consensus recommendations about which agent or
combinations of agents should be used as initial treatment

– Asymptomatic AMR treatment options

– Blood transfusions

– Hyperacute

• Patient received basiliximab and methylprednisone intra-operatively

• Treatment options are aimed at reducing the presence of donor-specific
antibodies

– Pregnancy

• Types of AMR

• Overall intra-operative course was uncomplicated

• Treatment algorithms vary among institutions

Complement

– Antibodies activate complement system
– Leads to cell death and tissue necrosis

• Patient received transplant of both organs May 2013
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– Dilated cardiomyopathy
– Embryonal vaginal rhabdomyosarcoma with bladder wall involvement – treated
with cisplatin and an anthracycline-based chemotherapy at age 3

CONCLUSION
• Rituximab was effective in treating AMR in this patient
• The growing data on the use of rituximab for AMR may have important
implications for the design of treatment regimens in patients with
heart and kidney transplants
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– Highest intensity with fluorescence

• Patient was listed for heart and kidney transplant in April 2013
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